Go Pro
→ Someone just dumped the biggest gold fund. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$26.10
+0.5%		$23.68
$11.92
▼
$27.31
$4.85B1.072.17 million shs1.18 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$44.18
+2.1%		$41.15
$13.69
▼
$48.40
$4.70B0.31.35 million shs1.25 million shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$14.30
-3.2%		$20.13
$4.51
▼
$25.77
$1.26B1.591.52 million shs969,084 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$39.36
-0.6%		$31.59
$24.51
▼
$41.49
$4.68BN/A353,828 shs354,610 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.46%+1.56%+12.45%+50.26%+118.05%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
+2.06%+0.02%+15.26%+35.11%+219.22%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-3.25%-7.74%-39.89%-23.98%+222.80%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-0.56%+6.18%+27.75%+3,935,999,900.00%+3,935,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$26.10
+0.5%		$23.68
$11.92
▼
$27.31
$4.85B1.072.17 million shs1.18 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$44.18
+2.1%		$41.15
$13.69
▼
$48.40
$4.70B0.31.35 million shs1.25 million shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$14.30
-3.2%		$20.13
$4.51
▼
$25.77
$1.26B1.591.52 million shs969,084 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$39.36
-0.6%		$31.59
$24.51
▼
$41.49
$4.68BN/A353,828 shs354,610 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.46%+1.56%+12.45%+50.26%+118.05%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
+2.06%+0.02%+15.26%+35.11%+219.22%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-3.25%-7.74%-39.89%-23.98%+222.80%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-0.56%+6.18%+27.75%+3,935,999,900.00%+3,935,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.87
Moderate Buy$34.4231.86% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$50.3313.93% Upside
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.67
Moderate Buy$28.5099.30% Upside
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
3.00
Buy$41.675.86% Upside

Current Analyst Ratings Breakdown

Latest GLUE, DYN, EWTX, and PBLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$53.00 ➝ $60.00
8/17/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/11/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$32.00 ➝ $36.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$35.00 ➝ $28.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$31.00 ➝ $27.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$29.00 ➝ $27.00
8/4/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/3/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$37.00 ➝ $27.00
7/31/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$47.00 ➝ $45.00
7/30/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $35.00
(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$3.76 per shareN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.13 per shareN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$28.73M42.47N/AN/A$5.71 per share2.50
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%11/5/2026 (Estimated)
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$38.63M-$1.76N/AN/AN/A-560.85%-43.31%-27.59%11/5/2026 (Estimated)
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest GLUE, DYN, EWTX, and PBLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$0.16-$2.32-$2.16-$2.32N/A$0.15 million
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
8/6/2026Q2 2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.3805-$0.43-$0.0495-$0.43$12.91 million$8.97 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
10.58
10.58
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A

Insider Ownership

CompanyInsider Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.40%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100186.75 million169.08 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60108.60 million85.47 millionOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9085.31 million79.85 millionOptionable
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A118.15 millionN/AN/A

Recent News About These Companies

Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9% - Here's What Happened
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-nasdaqpbls-stock-price-up-59-heres-what-happened-2026-08-18/
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alphabet-inc-makes-new-13465-million-investment-in-parabilis-medicines-inc-pbls-2026-08-18/
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year High - What's Next?
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-nasdaqpbls-sets-new-1-year-high-whats-next-2026-08-17/
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936772-parabilis-medicines-a-rare-tumor-validation-ladder-for-an-undruggable-platform
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/parabilis-medicines-q2-loss-narrows-114633847.html
Parabilis Medicines: Q2 Earnings Snapshot
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/parabilis-medicines-q2-earnings-snapshot-110720376.html
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344336/0/en/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates.html
Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year High - What's Next?
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-nasdaqpbls-reaches-new-1-year-high-whats-next-2026-08-10/
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-inc-nasdaqpbls-given-average-recommendation-of-buy-by-analysts-2026-08-01/
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
July 6, 2026  |  benzinga.comhttps://www.benzinga.com/news/26/07/60274173/this-parabilis-medicines-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday?utm_source=snapi
PBLS Parabilis Medicines, Inc.
July 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/PBLS/sec-filings
Guy Levy Acquires 500,000 Shares of Parabilis Medicines (NASDAQ:PBLS) Stock
June 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pbls-insider-buying-and-selling-2026-06-30/
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
June 27, 2026  |  fool.comhttps://www.fool.com/investing/2026/06/27/this-little-known-biotech-just-delivered-a-bigger/
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
June 20, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/20/fresh-off-ipo-a-director-buys-usd474-000-of-parabilis-medicines-stock-is-pbls-a-buy/
Insider Buying: Parabilis Medicines (NASDAQ:PBLS) Director Acquires 8,435 Shares of Stock
June 17, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pbls-insider-buying-and-selling-2026-06-17/
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
June 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/parabilis-medicines-pbls-stock-valuation-211405848.html
StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO
June 14, 2026  |  genengnews.comG
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/parabilis-medicines-announces-closing-upsized-200500345.html
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials
May 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4908000-parabilis-medicines-starts-ipo-on-promising-cancer-therapy-trials

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
L3Harris logo on a panel with a satellite, drone, camera sensor, and network icons against a sunset sky.
L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
By Thomas Hughes | July 31, 2026
Autonomous mobile robots carrying storage bins move through an automated factory production line with illuminated blue accents.
3 Robotics Stocks Under $10: Value, Momentum, or Bet?
By Chris Markoch | August 17, 2026
Medical imaging scanner with exposed internal components being assembled in a manufacturing facility with computer workstations.
Inside Teledyne's Bold Bet on the Future of Medical Imaging
By Jeffrey Neal Johnson | August 14, 2026
Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$26.10 +0.12 (+0.46%)
As of 08/21/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$44.18 +0.89 (+2.06%)
As of 08/21/2026 04:00 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$14.30 -0.48 (-3.25%)
As of 08/21/2026 04:00 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Parabilis Medicines stock logo

Parabilis Medicines NASDAQ:PBLS

$39.36 -0.22 (-0.56%)
As of 08/21/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas